Amgen 2012 Annual Report Download - page 3

Download and view the complete annual report

Please find page 3 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

pharmaceutical market in the world, through
partnership; and we are pursuing an entry into
China, where we expect to be launching our first
product by 2015.
As Amgen grows globally, we expect to reach
more patients with the medicines we currently
have on the market and with therapies from our
late-stage pipeline. A great example of the latter
is rilotumumab (AMG 102), a medicine in phase
3 development for the treatment of gastric
cancer. Every year, more than half a million
people die of this disease in Asia. Bringing this
new therapy to this region of the world could
represent a very big opportunity to serve a large
unmet medical need.
Smooth Leadership Transition
In 2012, Amgen began the execution of a
planned leadership transition with the retirement
of Kevin Sharer, Amgen’s third chairman and
chief executive officer. I would like to recognize
the extraordinary leadership of my friend and
predecessor. Kevin retired from Amgen after a
20-year career with the company, which included
12 years as chief executive officer. Simply put,
Amgen would not be the company it is today
were it not for Kevin’s leadership and
determination to make Amgen the world’s best
human therapeutics company. One of the ways
we will honor Kevin’s legacy is by building upon
his many accomplishments—and by maintaining
focus on our mission to serve patients.
In my first year as chief executive officer, I have
had the opportunity to speak with hundreds of
our staff around the world; and regardless of
which facility I visit, my impression is the same:
we are strongly aligned with our mission to serve
patients. Having also spent time with doctors,
other healthcare providers, and patients, I have
found that our constituents see the benefits of
our approach to unlocking the potential of
biology for patients through advancing break-
through medicines and manufacturing those
medicines safely and effectively.
Looking ahead, I am confident that we will
deliver for patients and shareholders. Our
strategy is sound, our staff members are aligned,
and our culture—rooted in science and
innovation—is strong, having enabled us to
reach more than 25 million patients around the
world with our medicines.
Robert A. Bradway
Chairman and Chief Executive Officer
Awards and Accolades
•R&D Directions: For the second year in a row,
Amgen received Best Biotech Pipeline honors
from R&D Directions.
•Most Innovative Drug of the Year: Amgen
Poland was awarded the title for Prolia®
(denosumab) in a competition organized by the
Working Group for Innovation in Healthcare.
•Prix Galien: Prolia® (denosumab) was awarded
the Prix Galien in Switzerland, judged by a panel
of eminent clinicians, toxicologists, pharmacolo-
gists, and pharmacists.
•Panorama Award: Prolia® (denosumab)
received top honors in Spain in 2012 by receiving
the Panorama Award for The Most Innovative
Treatment of 2011.
•NORD Partners in Progress Corporate Award:
Amgen received the National Organization for
Rare Diseases (NORD) Partners in Progress
Corporate Award for our role in bringing
Sensipar® (cinacalcet) to patients for the
treatment of severe hypercalcemia in patients
with primary hyperparathyroidism (PHPT) who are
unable to undergo parathyroidectomy. The annual
award is presented to companies that have
developed new treatments for rare diseases.
•Great Place to Work Institute: Amgen’s Dutch
affiliate was recognized as one of the top places
to work in the Netherlands.